Our People on the Move column tracks pharma's movers and shakers.
Biogen Idec has hired Donald Johns as Vice President to lead its amyotrophic lateral sclerosis (ALS) Innovation Hub (ALS iHub).
The iHub is a new unit dedicated to accelerating the discovery and development of novel therapies for ALS by integrating research with clinical development. The disease is also known as motor neurone disease and Lou Gehrig’s disease.
Johns has worked for more than 30 years developing novel drugs for neurodegenerative diseases, and has 14 pending or issued patents to his name. He joins Biogen Idec from Novartis Institutes for BioMedical Research, where he was global head of Neuroscience Translational Medicine.
The ALS drug discovery cause has hit the news since July, when the ‘Ice Bucket Challenge’ went viral on social media, encouraging people to dump buckets of ice water over their heads to raise funds for ASL research. Cristiano Ronaldo, George W. Bush (pictured), Britney Spears and Tom Cruise are among the celebrities who have been filmed doing the challenge.
Copyright - Unless otherwise stated all contents of this web site are © 2016 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions
The world’s largest modular cGMP biopharmaceutical manufacturing facility came online this week in Wuhan, China.
Valeant, Rentschler, Celgene, MannKind, and Syngene are among those welcoming new leaders for 2016. Oh, and Turing...